KOL Views: Is AB Science’s masitinib the next big thing in MS – or a thing at all?

Masitinib has an interesting track record characterised by “positive” top-line readouts in conditions like amyotrophic lateral sclerosis (ALS), mastocytosis and severe asthma, though it has yet to pass muster with regulators. AB Science added another possible indication to the mix last week when the company reported that masitinib met the primary endpoint in a Phase II/III trial for progressive forms of multiple sclerosis (MS).

To provide FirstWord readers with rapid feedback on what to make of masitinib’s initial success in the MS space, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… initial thoughts on masitinib’s profile and rationale for using an immunomodulatory agent targeting mast cells and macrophages to treat MS; how do masitinib “positive” top-line readouts in other indications impact your perception of the programme; are you surprised, impressed and/or sceptical about this positive top-line readout; reaction to the efficacy findings that have been disclosed so far in Phase II and Phase III testing for MS; are there any notable safety concerns; what are the biggest question marks at this point and what will you want to look most closely at when detailed data are presented and/or published; does this have the potential to be a big breakthrough in MS or does it seem more likely – even if it is indeed effective – to be more of a niche product; how likely is an eventual approval of masitinib in MS?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment landscape in MS and masitinib’s potential place in it.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.